A leading-edge immunotherapy may extend survival for patients with one of the most aggressive forms of blood cancer, according to newly published five-year results from a major clinical trial in the Blood Journal. The clinical trial evaluated lisocabtagene maraleucel (liso-cel), a type of chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL),…
Source: Medical Xpress
